This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Somasiri, A. Articles by Roskelley, C. D. Search for Related Content PubMed PubMed Citation Articles by Somasiri, A. Articles by Roskelley, C. D.

Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression

¹ Department of Anatomy and Cell Biology and the ² Biomedical Research Center, University of British Columbia, Vancouver, British Columbia, Canada; ³ Genetic Pathology Evaluation Center, Vancouver Hospital, Vancouver, British Columbia, Canada; ⁴ Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and ⁵ Deptartment of Pediatrics, University of Michigan Medical Center, Ann Arbor, Michigan

Podocalyxin is a CD34-related cell surface molecule with anti-adhesive qualities. We probed a tissue microarray (n = 272) linked to long-term outcome data and found that podocalyxin was highly overexpressed in a distinct subset of invasive breast carcinomas (n = 15; 6%). Univariate disease-specific (P < 0.01) and multivariate regression (P < 0.0005) analyses indicated that this overexpression is an independent indicator of poor outcome. Forced podocalyxin expression perturbed cell junctions between MCF-7 breast carcinoma cells, and it caused cell shedding from confluent monolayers. Therefore, podocalyxin overexpression is a novel predictor of breast cancer progression that may contribute to the process by perturbing tumor cell adhesion.

This article has been cited by other articles:

				J. S. Nielsen and K. M. McNagny The Role of Podocalyxin in Health and Disease J. Am. Soc. Nephrol., August 1, 2009; 20(8): 1669 - 1676. [Abstract] [Full Text] [PDF]

				S. N. Thomas, R. L. Schnaar, and K. Konstantopoulos Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells Am J Physiol Cell Physiol, March 1, 2009; 296(3): C505 - C513. [Abstract] [Full Text] [PDF]

				J. S. Nielsen and K. M. McNagny Novel functions of the CD34 family J. Cell Sci., November 15, 2008; 121(22): 3683 - 3692. [Abstract] [Full Text] [PDF]

				H Yasuoka, M Tsujimoto, M Hirokawa, M Tori, M Nakahara, A Miyauchi, R Kodama, T Sanke, and Y Nakamura Podocalyxin expression in undifferentiated thyroid carcinomas J. Clin. Pathol., November 1, 2008; 61(11): 1228 - 1229. [Full Text] [PDF]

				S. C. Kerr, C. B. Fieger, K. R. Snapp, and S. D. Rosen Endoglycan, a Member of the CD34 Family of Sialomucins, Is a Ligand for the Vascular Selectins J. Immunol., July 15, 2008; 181(2): 1480 - 1490. [Abstract] [Full Text] [PDF]

				J. S. Nielsen and K. M. McNagny Influence of host irradiation on long-term engraftment by CD34-deficient hematopoietic stem cells Blood, August 1, 2007; 110(3): 1076 - 1077. [Full Text] [PDF]

				P. Sathyanarayana, M. P. Menon, O. Bogacheva, O. Bogachev, K. Niss, W. S. Kapelle, E. Houde, J. Fang, and D. M. Wojchowski Erythropoietin modulation of podocalyxin and a proposed erythroblast niche Blood, July 15, 2007; 110(2): 509 - 518. [Abstract] [Full Text] [PDF]

				S. Sizemore, M. Cicek, N. Sizemore, K. P. Ng, and G. Casey Podocalyxin Increases the Aggressive Phenotype of Breast and Prostate Cancer Cells In vitro through Its Interaction with Ezrin Cancer Res., July 1, 2007; 67(13): 6183 - 6191. [Abstract] [Full Text] [PDF]

				E. A. Ostrander, E. M. Kwon, and J. L. Stanford Genetic susceptibility to aggressive prostate cancer. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1761 - 1764. [Full Text] [PDF]

				R. J. Steagall, A. E. Rusinol, Q. A. Truong, and Z. Han HSPA12B Is Predominantly Expressed in Endothelial Cells and Required for Angiogenesis Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2012 - 2018. [Abstract] [Full Text] [PDF]

				J. M. Lee, S. Dedhar, R. Kalluri, and E. W. Thompson The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol., March 27, 2006; 172(7): 973 - 981. [Abstract] [Full Text] [PDF]

				G. Casey, P. J. Neville, X. Liu, S. J. Plummer, M. S. Cicek, L. M. Krumroy, A. P. Curran, M. R. McGreevy, W. J. Catalona, E. A. Klein, et al. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness Hum. Mol. Genet., March 1, 2006; 15(5): 735 - 741. [Abstract] [Full Text] [PDF]

				H.-Y. Cheng, Y.-Y. Lin, C.-Y. Yu, J.-Y. Chen, K.-F. Shen, W.-L. Lin, H.-K. Liao, Y.-J. Chen, C.-H. Liu, V. F. Pang, et al. Molecular Identification of Canine Podocalyxin-Like Protein 1 as a Renal Tubulogenic Regulator J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1612 - 1622. [Abstract] [Full Text] [PDF]

				R. Doyonnas, J. S. Nielsen, S. Chelliah, E. Drew, T. Hara, A. Miyajima, and K. M. McNagny Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells Blood, June 1, 2005; 105(11): 4170 - 4178. [Abstract] [Full Text] [PDF]